Stock Screener App

Frei -

Installieren

0.9094

2.12% -0.0197

Citius Oncology Inc (CTOR)

Überblick Nachrichten Preisverlauf Forum Prognose

Citius Oncology Inc Aktie (CTOR) Neueste Nachrichten

CTXR News | CITIUS PHARMACEUTICALS INC (NASDAQ:CTXR) - ChartMill

Citius Pharmaceuticals to Participate in September 2026 Investor Conferences - PR Newswire

CTXR Stock Price, Quote & Chart - ChartMill

Citius (CTOR) Quarterly Results: The EPS Result Is Below Expectation in the Latest Session; Session Move: Shares Finish 2.02% Lower on the DayEPS Surprise History - vinanet.vn

Enterprise value to EBIT forward of Citius Oncology, Inc. – NASDAQ:CTOR - TradingView

Armistice Capital Expands Citius Oncology (CTOR) Stake Despite Distress Signals - GuruFocus

Citius (CTOR) Quarterly Results: Reported EPS Misses Expectations in the Reported Period; After Results: The Market Price Advances 6.97% on the DayForward Guidance Trends - vinanet.vn

Citius Oncology Shares Slide 10% After Fiscal Q3 Revenue Misses Estimates Despite LYMPHIR Launch Gains - dars.gov.et

Citius Oncology shares tumble as Q3 revenue misses forecasts despite LYMPHIR launch momentum - Yahoo Finance

Citius Oncology stock tumbles 10% on revenue miss despite launch progress - Investing.com Australia

Citius Oncology (CTOR) Institutional Ownership 2026 $CTOR - MarketBeat

CTOR Q2 2026 Earnings: Pre-Revenue Loss Misses Badly, Yet Shares Jump 10%EBITDA Analysis - vinanet.vn

Breakeven On The Horizon For Citius Oncology, Inc. (NASDAQ:CTOR) - simplywall.st

Citius Pharma Reports First LYMPHIR Revenue of $7.1M in Nine Months - Minichart

Citius Oncology Posts First Revenue from LYMPHIR Launch as Institutional Demand Surges 31% - Minichart

Citius Oncology (NASDAQ:CTOR) Posts Quarterly Earnings Results, Misses Expectations By $0.01 EPS - MarketBeat

Citius Oncology (CTOR) director Jonathan Peri files Form 3 showing no common shares - Stock Titan

Citius Pharma Q3 EPS beats estimate, sales miss by 72% - scanx.trade

Citius Oncology Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Citius Pharmaceuticals Reports Q3 2026 Financial Results and LYMPHIR Progress - Intellectia AI

CTOR: LYMPHIR launch drove $7.1M revenue and 31% sequential vial order growth, with broad payer access - TradingView

Citius Oncology (CTOR) grows LYMPHIR sales but posts $41M nine-month loss - Stock Titan

Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update - PR Newswire

Citius Oncology (CTOR) Advances 5.5% to $0.87 as Buyers Defend Support ZoneInverse ETF Flow - vinanet.vn

Citius Oncology (CTOR) investor reports 9.99% beneficial ownership stake - Stock Titan

Citius Oncology appoints independent director Peri to board of directors - ROI-NJ

Citius Oncology appoints Jonathan Peri to board of directors By Investing.com - Investing.com Australia

People on the Move: Jonathan Peri, Ph.D., J.D., Joins Citius Oncology’s Board of Directors - BioBuzz

Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri - Morningstar

Citius Pharmaceuticals expands Citius Oncology board to nine with appointment of Jonathan Peri - Traders Union

Form 8K Citius Oncology Inc For: 12 August By Investing.com - Investing.com South Africa

Citius Oncology adds independent director to expanded board - TipRanks

Citius Oncology Adds Jonathan Peri to Board as LYMPHIR Commercialization Advances - citybiz

Citius Oncology appoints Jonathan Peri to board of directors - Investing.com

Citius Oncology (CTOR) Expected to Announce Earnings on Tuesday - MarketBeat

Citius Oncology Inc (CTOR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Citius Oncology Inc expected to post a loss of 5 cents a shareEarnings Preview - TradingView

CTOR Q2 2026 Earnings: Deep EPS Miss Highlights Development-Stage Cash Burn ChallengesDividend Earnings Report - vinanet.vn

Citius Oncology of Cranford says commercial response to cancer treatment is strong - ROI-NJ

LYMPHIR orders rise 78% QoQ as Citius Oncology expands market access for CTCL treatment. - Pluang

Citius Oncology reports strong LYMPHIR U.S. launch momentum - TipRanks

Citius Oncology reports strong LYMPHIR commercial momentum - TipRanks

Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment - PR Newswire

Citius Oncology (CTOR) Adds 3.22% as Shares Hold Above $0.56 SupportOBV Breakout - vinanet.vn

CTOR|Citius Oncology Inc|Price:0.654|Chg%:+0.062 - TradingKey

CTOR Q2 2026 Earnings: Significant EPS Miss Highlights Ongoing Development StageNon-GAAP Earnings - vinanet.vn

Citius Oncology Inc (CTOR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Citius Oncology Inc (CTOR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Citius Oncology, Inc. Revenue Breakdown – NASDAQ:CTOR - TradingView

Citius Oncology Inc (CTOR) Balance Sheet - TradingKey

Citius Oncology Inc (CTOR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Citius Oncology Inc (CTOR) Income Statement - TradingKey

TradingKey - TradingKey

Citius Oncology Inc (CTOR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

CTOR|Citius Oncology Inc|Price:0.562|Chg%:-0.016 - TradingKey

CTOR|Citius Oncology Inc|Price:0.570|Chg%:+0.008 - TradingKey

Citius Oncology Inc (CTOR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

ALKS

$45.42

0.22%

RDY

$11.83

0.34%

ELAN

$23.71

1.07%

NBIX

$153.68

0.97%

VTRS

$16.45

0.93%

UTHR

$503.48

1.06%

In Yahoo öffnen | In Google öffnen | In Finviz öffnen | In MarketWatch öffnen | Öffnen Sie in EDGAR | Offen in Reuters